Annales d'endocrinologie · 2026
Determinants of Glycemic Control with Automated Insulin Delivery in adults living with type 1 diabetes: A 12-Month Sub-Analysis of the French OB2F Registry.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Joubert Michael, Julla Jean-Baptiste, Renard Eric, Lablanche Sandrine, Sola Agnès, Cosson Emmanuel, Donnet Jean-Paul, Sonnet Emmanuel, Vambergue Anne, Fendri Salah, Marchand Lucien, Lemoine Amal, Kessler Laurence, Giraud Mathieu, Banu Isabela, Rocha Elise Pinto Da, Vatier Camille, Plat Françoise, Carlier Aurélie, Gautier Jean-François, Riveline Jean-Pierre, OB2F Study Group
Аннотация
OBJECTIVE: To identify baseline determinants of achieving international continuous glucose monitoring (CGM) targets after 12 months of automated insulin delivery (AID) in adults with type 1 diabetes.
RESEARCH DESIGN AND METHODS: This predefined sub-analysis of the nationwide French OB2F registry included adults with type 1 diabetes initiating MiniMed 780G or Tandem Control-IQ in 2022. Participants required ≥14 consecutive days of CGM data at baseline and 12 months. The primary outcome was achievement of combined CGM targets at 12 months, defined as TIR >70% and TBR <4%. Baseline predictors were assessed using multivariable logistic regression.
RESULTS: Among 1,058 adults, 43% achieved combined CGM targets at 12 months (52% of MiniMed 780G users and 36% of Tandem Control-IQ users). Better baseline metabolic control, including higher TIR and lower HbA1c, TAR, GMI, and glucose variability, was independently associated with target achievement across both systems. Lower baseline TBR predicted target achievement only in MiniMed 780G users. GRI improved in both systems, from 44.1±19.4 to 30.2±13.6 with MiniMed 780G and from 49.4±20.0 to 36.7±14.9 with Tandem Control-IQ.
CONCLUSIONS: Baseline glycaemic profile is the main determinant of achieving international CGM targets after AID initiation in adults with type 1 diabetes, despite substantial improvement in those with poorer baseline control.
RESEARCH DESIGN AND METHODS: This predefined sub-analysis of the nationwide French OB2F registry included adults with type 1 diabetes initiating MiniMed 780G or Tandem Control-IQ in 2022. Participants required ≥14 consecutive days of CGM data at baseline and 12 months. The primary outcome was achievement of combined CGM targets at 12 months, defined as TIR >70% and TBR <4%. Baseline predictors were assessed using multivariable logistic regression.
RESULTS: Among 1,058 adults, 43% achieved combined CGM targets at 12 months (52% of MiniMed 780G users and 36% of Tandem Control-IQ users). Better baseline metabolic control, including higher TIR and lower HbA1c, TAR, GMI, and glucose variability, was independently associated with target achievement across both systems. Lower baseline TBR predicted target achievement only in MiniMed 780G users. GRI improved in both systems, from 44.1±19.4 to 30.2±13.6 with MiniMed 780G and from 49.4±20.0 to 36.7±14.9 with Tandem Control-IQ.
CONCLUSIONS: Baseline glycaemic profile is the main determinant of achieving international CGM targets after AID initiation in adults with type 1 diabetes, despite substantial improvement in those with poorer baseline control.